Eptapirone

| Cat. No.: | HY-19946 | | |
|--------------------|---|-------|---------|
| CAS No.: | 179756-58-2 | | |
| Molecular Formula: | C ₁₆ H ₂₃ N ₇ O ₂ | | |
| Molecular Weight: | 345.4 | | |
| Target: | 5-HT Receptor | | |
| Pathway: | GPCR/G Protein; Neuronal Signaling | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 2 years |
| | | -20°C | 1 year |

®

MedChemExpress

SOLVENT & SOLUBILITY

| In Vitro | DMSO : 250 mg/mL (7 | DMSO : 250 mg/mL (723.80 mM; Need ultrasonic) | | | | | |
|------------------------------|---|---|-----------|------------|------------|--|--|
| Preparing Stock Solutions | Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg | | |
| | | 1 mM | 2.8952 mL | 14.4760 mL | 28.9519 mL | | |
| | 5 mM | 0.5790 mL | 2.8952 mL | 5.7904 mL | | | |
| | 10 mM | 0.2895 mL | 1.4476 mL | 2.8952 mL | | | |
| | Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution | | | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution | | | | | | |
| | 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.24 mM); Clear solution | | | | | | |

| Diological Activity | | | | | |
|---------------------------|---|--|--|--|--|
| Description | Eptapirone (F11440) is a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. | | | | |
| IC ₅₀ & Target | 5-HT _{1A} Receptor | | | | |
| In Vitro | The affinity of Eptapirone (F11440) for 5-HT1Abinding sites (pKi, 8.33) was higher than that of buspirone (pKi , 7.50), and somewhat lower than that of flesinoxan (pKi , 8.91).In vivo, Eptapirone (F11440) was 4- to 20-fold more potent than | | | | |

Product Data Sheet

N²

flesinoxan, and 30- to 60-fold more potent than buspirone, in exerting 5-HT1A agonist activity at pre- and postsynaptic receptors in rats (measured by, for example, its ability to decrease hippocampal extracellular serotonin (5-HT) levels and to increase plasma corticosterone levels, respectively). Eptapirone (F11440), shown here to be a potent, selective, high efficacy 5-HT1Areceptor agonist, appears to have the potential to exert marked anxiolytic and antidepressant activity in humans.[1] MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

| Cell Assay | Eptapirone (F11440) is dissolved in DMSO. The HeLa cell line permanently transfected with the human 5-HT1A receptor gene and permanently expressing the 5-HT1A receptor protein (HA7). In subsequent experiments, the maximum effect of Eptapirone (F11440) is compared with those of other compounds by repeated testing (n=9) at a concentration of 10 ⁻⁵ M (i.e., a concentration at which the reference compounds used here appeared to attain their maximal effects) in a first series of experiments and at 10 ⁻⁴ M in a second series. Data from each series were analyzed statistically by means of a one-way analysis of variance followed by sequential paired comparisons by means of Newman-Keuls tests ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
|---|--|
| Animal Administration ^[1] | Rats ^[1] For in vivo studies, F 11440 was suspended in distilled water by adding Tween 80 (2 drops/10 ml). When injected i.v., F 11440 was dissolved in a mixture of 60% PEG and 40% physiological saline. Doses are expressed as the weight of the free base. Twenty-four hours before use in the experiments, rats were housed individually in a restricted area (accessible only to the experimenter) and received 15 g standard laboratory food (water continued to be available freely). Experiments, consisting of drug treatments after which animals were decapitated and trunk blood was collected, were conducted between 8:00 a.m. and 10:30 a.m. F 11440 (or vehicle) was administered 60 min before decapitation when given p.o., and 30 min before decapitation when given i.p. ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

REFERENCES

[1]. Koek W, et al. F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. J Pharmacol Exp Ther. 1998 Oct;287(1):266-83.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA